Indeed, Dahan et al. reported that engagement of FcγRs reduced the anti-tumor activity of an anti-PD-1 antibody by eliminating CD8+ tumor-infiltrating lymphocytes via ADCC in a FcγRI-dependent manner10. The gene discussed is PDCD1; the disease is neoplasm.